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Abstract: Transforming growth factor beta (TGFβ) plays an important role in cancer, but 
accurate measurement of circulating TGFβ is complicated by the high TGFβ content of plate-
lets which can release TGFβ ex vivo. We evaluated the use of citrate-theophylline-adenosine-
dipyridamole (CTAD) tubes to reduce preanalytical variation in TGFβ measurements caused 
by ex vivo platelet activation. CTAD substantially reduced ex vivo platelet activation relative to 
traditional plasma collections in normal donors, which correlated with a decrease in measured 
TGFβ levels. We show that TGFβ levels are elevated in the majority of cancer patients with 
skeletal metastases, and that within-patient variability of these levels is relatively low over 
several weeks. Patients with elevated TGFβ could be subdivided into groups with or without 
evidence of platelet contribution to measured TGFβ levels. The use of CTAD tubes allows a 
better determination of a patient’s TGFβ status, and may improve classiﬁ  cation of patients 
with oncologic disease.
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Primary objective
Transforming growth factor β (TGFβ) is a dimeric 25 kD cytokine synthesized by 
multiple cell types. Three isoforms exist (TGFβ1, TGFβ2, and TGFβ3), of which 
TGFβ1 is the dominant form in humans. (For the remainder of this report, TGFβ will 
refer to TGFβ1 unless otherwise speciﬁ  ed). Although the majority of tissues in the 
human body are capable of synthesizing TGFβ under appropriate conditions, two of 
the tissues with the highest TGFβ content in normal donors are platelets (20 mg/kg) 
(Assoian and Sporn 1986) and bone (200 μg/kg) (Seyedin et al 1985). The role of 
TGFβ in normal biology is intricate and depends largely on the environment in which 
TGFβ is secreted. These actions can include suppression of cell proliferation, enhanced 
extracellular matrix deposition, and immunomodulatory effects (Blobe et al 2000). 
The role of TGFβ in cancer is even more complex, where TGFβ has been proposed 
to have roles as both a tumor suppressor in the premalignant phase of disease and as 
a pro-oncogenic factor in later stage metastatic disease (Roberts and Wakeﬁ  eld 2003; 
Siegel and Massague 2003). Because of this, TGFβ may play an important role in the 
pathological processes of cancer.
The use of TGFβ as a biomarker in cancer has been explored for years with 
varying success. Immunohistochemical analysis of biopsy material has shown 
increased TGFβ staining in many different tumor types (Gordinier et al 1999; Nio 
et al 2005), which correlated to clinical parameters such as metastasis and disease 
progression in some studies (Hazelbag et al 2004; Yamamoto et al 2004; Culhaci 
et al 2005). Because TGFβ is readily secreted by most cell types, a number of groups 
have evaluated the use of circulating TGFβ levels as a potential cancer biomarker. 
Results from such approaches have been variable, with some reports suggesting that Biologics: Targets & Therapy 2008:2(3) 564
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circulating TGFβ levels have clinical utility in predicting 
disease progression (Shariat et al 2001), while others show 
no relationship between circulating TGFβ and outcome 
(Wakeﬁ  eld et al 1995).
One factor that complicates the use of circulating 
TGFβ levels as a biomarker is the potential for ex vivo 
release of TGFβ from platelet stores due to platelet activa-
tion. It has long been appreciated that platelets are a rich 
source of TGFβ (Assoian and Sporn 1986), and that as a 
result serum measurements of TGFβ are largely driven by 
platelet count and do not accurately reﬂ  ect true circulating 
levels of TGFβ (Kropf et al 1997). As a result, plasma is 
the preferred matrix for TGFβ assessment. However, some 
level of platelet activation occurs even with routine plasma 
collection, and the amount of ex vivo activation can vary 
signiﬁ  cantly depending upon the type of anticoagulant tube 
used (Golanski et al 1996; Neufeld et al 1999; Philippe 
et al 2004). For this reason, methods to reduce the level of 
platelet activation in plasma samples would be useful to 
help limit overestimation of in vivo TGFβ levels due to ex 
vivo activation of platelets.
In this study, we have evaluated the use of citrate-
theophylline-adenosine-dipyridamole (CTAD) tubes as a 
means to provide more accurate TGFβ measurements in 
platelet-poor plasma from cancer patients. CTAD tubes 
contain citrate anticoagulant and a mixture of theophylline, 
adenosine, and dipyramidole, which serve to reduce ex 
vivo platelet activation by increasing cAMP and inhibiting 
calcium-mediated platelet activation (Contant et al 1983; 
Macey et al 2002). We have characterized the effects of this 
matrix on a commonly used TGFβ ELISA, and applied this 
approach to the measurement of TGFβ in healthy volun-
teers and in oncology patients with skeletal metastases. We 
demonstrate that CTAD tubes are an acceptable matrix for 
TGFβ analysis, and that the reduction of ex vivo platelet 
activation using these tubes leads to a concomitant reduction 
in measured TGFβ levels in healthy volunteers. Using this 
technique we demonstrate that the majority of oncology 
patients with skeletal metastases have elevations in circu-
lating TGFβ levels, and that the within-patient variability 
of these measurements are relatively low over a two-week 
period. In addition, the use of CTAD plasma coupled with 
measurement of platelet activation markers allows dif-
ferentiation of patients with or without substantial platelet 
contributions to measured TGFβ levels. This approach is 
an extension of the previous works showing that control of 
platelet activation is critical to the assessment of circulating 
TGFb levels (Reinhold et al 1997).
Methods and procedures
Patient population
After obtaining Institution Review Board approval of the 
clinical protocol and informed consent from patients, samples 
were collected from oncology patients from three different 
institutions as part of an ongoing clinical trial designed to 
examine TGFβ-related biomarkers (Baselga et al 2008). 
Patients were enrolled if they had previously-documented 
cancer involving skeletal metastases. 49 patients participated 
in this study, and CTAD tubes were collected 4 times over 
a 2–4 week period with no limitations on state at collection 
(diurnal, fasted.fed, etc). Patients received no oncolytic thera-
pies during this period. Tumor types in this study included 
breast cancer (23 patients), prostate cancer (15) multiple 
myeloma (7), renal cell carcinoma (3), and lymphoma (1).
Sample collection and TGFβ1 analysis
Samples were collected into either tripotassium ethylene-
diamine tetra-acetate (K3EDTA) or CTAD tubes (Becton, 
Dickinson and Co, Franklin Lakes, NJ). A modiﬁ  ed pro-
tocol was used for these collections. Brieﬂ  y, a tourniquet 
was initially used to locate the vein, then removed before 
collection. After removal of the tourniquet, a single discard 
tube was drawn to allow washout of any activation products 
caused by initiation of phlebotomy, followed by the CTAD 
tube. Tubes were then spun for 15 min at 2500 g, and the 
central portion of the plasma layer transferred to a second 
tube. This tube was then spun again for 15 min at 2500 g, 
and the supernatant transferred to a ﬁ  nal tube for storage at 
−70 °C until analysis.
TGFβ levels were analyzed using a commercially avail-
able ELISA (R&D Systems, Minneapolis, MN, catalog # 
DB100) per the manufacturer’s protocol. Brieﬂ  y, plasma 
samples underwent initial acidiﬁ  cation/neutralization steps 
immediately prior to analysis to activate latent TGFβ to an 
immunoreactive form, under conditions which have been 
shown to minimize re-association with TGFβ binding pro-
teins (Kropf et al 1997). The ELISA assay utilized soluble 
TGFβ type II receptor coated on the ELISA plate for antigen 
capture, with detection via a HRP-linked polyclonal speciﬁ  c 
for TGFβ1. Recombinant human TGFβ1 (rhTGFβ) included 
in the kit was used as a standard and for the spiking experi-
ments that follow below.
Analytical performance of the TGFβ1 assay in CTAD 
matrix was evaluated as follows: Assay precision was 
determined using 4 samples ranging from 0.05 ng/ml to 
15.8 ng/ml, which were run in triplicate in 5 runs over a 3 day 
period. Within- and between-day variance were expressed Biologics: Targets & Therapy 2008:2(3) 565
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as the coefﬁ  cient of variation (standard deviation/mean) 
for these samples. Matrix effects were assessed by spiking 
known concentrations of the rhTGFβ standard into CTAD 
samples, and evaluating recovery relative to buffer controls. 
Dilutional linearity was determined by performing a dilu-
tion series ranging from 1:2 to 1:20. Dilutions were run 
in triplicate, and the percent variation in observed values 
compared to expected results was calculated for each dilu-
tion. Freeze-thaw stability was assessed using 4 aliquots of 
samples stored at −70 °C which were subjected to between 
1 and 4 freeze-thaw cycles. All 4 aliquots were then assayed 
in triplicate in a single run.
Clinical trial samples were stored at −70 °C until the 
conclusion of the study, then batch analyzed for TGFβ 
levels. In addition to TGFβ, separate aliquots from these 
same CTAD plasma samples were also batch analyzed for 
two markers of platelet activation, platelet factor 4 (PF4) 
and beta-thromboglobulin (BTG) using commercial enzyme 
immunoassays (Asserachrom® PF4 and Asserachrom® BTG, 
both from Diagnostica Stago, Asnieres-Sur-Siene, France).
Main outcomes and results
Evaluation of CTAD matrix for TGFβ 
measurements
We initially examined the analytical performance of the 
TGFβ1 ELISA assay in CTAD plasma to ensure that this 
matrix did not adversely affect assay performance. As 
shown in Table 1, analytical parameters for the TGFβ1 
assay in CTAD plasma were comparable to that reported 
for EDTA plasma by the manufacturer (Table 1). Within- 
and between-day coefﬁ  cient of variation (CV) ranged from 
5.9%–13.4% and 9.1%–29%, respectively, with the highest 
variability seen at 0.05 ng/ml. The 0.05 ng/ml concentration 
was below manufacturer’s recommendations, but was 
initially evaluated in an attempt to extend the reportable 
range of the assay in the expectation that TGFβ levels in 
CTAD plasma would be lower than reported for EDTA 
plasma due to decreased platelet activation. No evidence 
of a matrix effect was seen in either the recovery or dilu-
tional linearity experiments, with less than 10% variation 
from expected results at most concentrations. Freeze-thaw 
stability of TGFβ was observed for two freeze-thaw cycles 
in CTAD with  10% loss of signal, but further freeze-thaw 
cycles led to a progressive loss of signal ( 15% change 
from original values).
Impact of CTAD tubes on ex vivo platelet 
activation and TGFβ measurement
Normal donor samples were next used to evaluate the dif-
ferences between EDTA and CTAD tubes on ex vivo TGFβ 
release, and to generate an estimate of the reference range 
for TGFβ in the CTAD matrix. Paired EDTA and CTAD 
tubes were drawn from 10 normal donors and evaluated for 
TGFβ as well as two markers of platelet activation, platelet 
factor 4 and beta-thromboglobulin. PF4 and BTG are con-
tained in platelet alpha granules in approximately equimolar 
amounts (Kaplan and Owen 1981), and are released follow-
ing platelet activation or platelet lysis. In our study, BTG 
and PF4 levels were both elevated in EDTA tubes relative 
to CTAD for all donors, conﬁ  rming that CTAD confers an 
advantage in limiting ex vivo platelet activation relative to 
EDTA (Figure 1A). A concurrent increase in TGFβ levels 
was also seen in the EDTA tubes from all donors, resulting 
in a 67%–430% bias in TGFβ levels in the EDTA plasma 
relative to the CTAD plasma (Figure 1B). An additional 
15 CTAD samples were then drawn from normal donors 
Table 1 Analytical performance of TGFβ ELISA in CTAD matrix
     CTAD  EDTA
Precision  Within-day  Concentrations tested (ng/ml)  0.05, 0.2, 8.0,15.8  0.88, 5.14, 11.13
    CV  13.4%, 8.3%, 5.8%, 5.9%  7.3%, 4.9%, 3.7%
  Between-day  Concentrations tested (ng/ml)  0.05, 0.2, 8.0, 15.8  1.18, 4.23, 7.21
    CV  29%, 10.8%, 11.5%, 9.1%  12.7%, 10.3%, 9.8%
Reportable range      0.75–240 ng/ml  0.36–240 ng/ml
Dilutional linearity    Dilutions tested  1:2, 1:5, 1:10, 1:20  1:2, 1:4
    % of expected value  100%, 98%, 97%, 120%  103%, 103%
Freeze-thaw stablility      Stable to 2 freeze/thaw cycles  NR
Notes: Experiments were performed as described in methods. CVi and % values are listed in order corresponding to tested concentrations for all experiments. Performance 
parameters in EDTA were taken from the manufacturer’s package insert for the TGFβ ELISA. The analytical performance of the assay in CTAD plasma was comparable with 
that reported for EDTA plasma.
Abbreviations: CTAD, citrate-theophylline-adenosine-dipyridamole; CVi, within-patient variability; EDTA, ethylenediamine tetra-acetate; NR, not reported; TGFβ, transforming 
growth factor beta.Biologics: Targets & Therapy 2008:2(3) 566
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to estimate the reference range for TGFβ in this matrix. 
The median TGFβ level from all 25 samples was 1.3 ng/ml 
(range 0.8–2.2 ng/ml), with a 95th percentile of 1.7 ng/ml, 
which was established as the upper limit of normal for the 
following oncology study.
Levels and variability of TGFβ 
measurements in oncology patients 
with advanced disease
A total of 188 samples were collected in CTAD tubes from 
49 oncology patients, and TGFβ, PF4 and BTG levels were 
measured as described. A surprising observation in this study 
was that 118 samples (63%) showed evidence of platelet 
activation, despite the use of CTAD tubes. There was good 
correlation between the two platelet activation markers in 
individual samples, with the majority of samples showing 
agreement between PF4 and BTG (Figure 2A). TGFβ levels 
were signiﬁ  cantly increased in the samples from oncology 
patients relative to normal donors (p   0.05, t-test), with 
77% of the samples collected falling above the upper limit of 
normal established in the healthy donor population. As one 
would expect, samples with evidence of platelet activation 
showed the highest levels of TGFβ (Figure 2B). However, 
TGFβ levels were also elevated in approximately half of 
the samples with normal PF4 and BTG levels, suggesting 
that in those patients TGFβ elevation may be driven by a 
mechanism independent of platelet release (such as elevated 
in vivo production of TGFβ from another source).
We next considered the within-patient variability (CVi) 
of TGFβ levels in the 47 patients who had at least 3 samples 
collected. The median CVi was relatively low for these 
patients (22.7%), with the majority of patients showing 
 40% variation in TGFβ levels over the two week period 
tested (Figure 3A). In addition to this consistency in TGFβ 
levels, an interesting ﬁ  nding was that many patients also 
showed consistent patterns of platelet activation markers 
over repeated visits. The variability of TGFβ measurements 
was lowest in the patients who had consistently normal PF4 
and BTG levels, while high CVi values were more common 
in the patients showing evidence of platelet activation. This 
increased variability in the platelet-activated subset was not 
simply attributable to an increase in measured TGFβ levels, 
as many patients with high TGFβ levels showed relatively 
low CVi (Figure 3B).
Conclusions
In this study we have shown that CTAD tubes are a suit-
able anticoagulant for TGFβ analysis, and that a com-
mercially available TGFβ1 ELISA assay shows acceptable 
Figure 1 Effect of CTAD matrix on platelet activation and TGFβ measurements. A) Markers of platelet activation. Both PF4 and BTG were substantially elevated in samples 
collected in EDTA tubes from normal donors, conﬁ  rming that some level of ex vivo platelet activation occurs in EDTA plasma draws. (Open symbols represent values outside 
the range of the assay). B) Within-donor TGFβ levels in CTAD and EDTA tubes. EDTA TGFβ levels were higher than CTAD tube levels for all donors, ranging from 1.7- to 
5.3-fold higher.
Abbreviations: BTG, beta-thromboglobulin; CTAD, citrate-theophylline-adenosine-dipyridamole; EDTA, ethylenediamine tetra-acetate; PF4, platelet factor 4; TGFβ, transforming 
growth factor beta.
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performance characteristics in this matrix. As predicted, 
the use of CTAD tubes led to a decreased level of ex vivo 
platelet activation when compared to traditional plasma 
collections in K3EDTA, which corresponded to a decrease 
in measured TGFβ levels in normal donors. The contribu-
tion of ex vivo platelet activation on TGFβ levels in normal 
donors was substantial in EDTA, resulting in as much as a 
5-fold increase in measured TGFβ in these samples. We have 
seen similar results with VEGF analysis in CTAD vs EDTA 
tubes (data not shown), and a recent publication has shown 
similar results for a number of platelet-derived growth factors 
including TGFβ (Zimmermann et al 2005), suggesting that 
this approach may be relevant to the measurement of many 
circulating cytokines.
Figure 2 CTAD plasma TGFβ levels in normal donors and oncology patients. A) Relationship of platelet-activation markers in clinical samples. Dashed lines represent the 
upper limit of normal for both markers, %’s indicated fraction of all samples falling in each quadrant. The overall correlation between platelet activation markers was good across 
all samples (r2 = 0.71, Pearson correlation coefﬁ  cient), with agreement between PF4 and BTG in 85% of the samples. B) TGFβ levels in oncology patients related to platelet 
activation. Boxes represent the median and central 50th percentile of observations, whiskers represent the 10th and 90th percentiles with individual outliers noted, dashed 
line represents upper limit established in normal donors (1.7 ng/ml). A single sample with an extremely elevated TGFβ level (13.2 pg/ml, BTG/PF4 +ve) is not shown to improve 
scaling. Samples collected from oncology patients had signiﬁ  cantly higher circulating TGFβ levels than those from normal donors (p   0.05 students t-test for all groups when 
compared to normal donors). This was true regardless of platelet activation status, although TGFβ levels were higher in samples with evidence of platelet activation.
Abbreviations: BTG, beta-thromboglobulin; CTAD, citrate-theophylline-adenosine-dipyridamole; PF4, platelet factor 4; TGFβ, transforming growth factor beta.
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TGFβ levels were elevated in the majority of the oncology 
patients enrolled in this trial. This was not entirely unex-
pected, as enrollment was limited to patients with skeletal 
metastases which is a population where TGFβ has been 
shown to play a signiﬁ  cant role (Kang et al 2005). There 
were substantial differences in TGFβ levels between patients, 
with average levels over the 4 visits ranging from 1.2–8.5 
ng/ml across the groups of patients enrolled. However, even 
with this wide range of TGFβ values across the population, 
within-patient variability was relatively low in most patients. 
This is encouraging for potential use of TGFβ as a biomarker, 
because it implies that limited sampling would be required 
to accurately assess a patient’s TGFβ status. We believe that 
the use of CTAD tubes contributed to this consistency, by 
reducing the variability that would be introduced by sporadic 
ex vivo platelet activation during the collection process. This 
is supported by the observation that the subset of patients 
where PF4 and BTG were sporadically elevated showed the 
highest levels of within-patient variability.
A surprising observation in this study was that a large 
number of samples showed elevated levels of BTG and 
PF4 despite the use of CTAD tubes to limit ex vivo platelet 
activation. The cause of this is not clear. One possibility is 
that this represents ex vivo platelet activation, either due to 
poor sample processing or an inherent increase in platelet 
reactivity in some oncology patients. Alternatively, the 
elevations in PF4 and BTG may indicate an increased in 
vivo platelet activation in a subset of these oncology patients. 
This would explain the within-patient consistency of activa-
tion marker patterns across multiple visits, and could reﬂ  ect 
the hypercoagulable state commonly found in patients with 
advanced cancer (Caine et al 2002). It is interesting to note 
that patients with elevated TGFβ levels in this study can be 
largely divided into two groups using these platelet markers. 
Patients with repeated evidence of platelet activation showed 
the highest levels of TGFβ, consistent with the observation 
that platelets contain large amounts of TGFβ. However, an 
additional group of patients had elevations of TGFβ in the 
absence of any evidence of platelet activation. It is possible 
that these patients represent a subset where TGFβ secretion 
from the tumor milieu is the primary driver of elevated 
circulating levels. Further work will be required to deﬁ  ne if 
there is any biological relevance to differentiating between 
these subgroups in terms of predicting either the disease 
prognosis or response to TGFβ-targeted therapies.
In summary, we believe that the use of CTAD tubes 
coupled with PF4 and BTG measurements will improve 
the ability to accurately assess a patient’s true TGFβ 
status by reducing the background noise introduced by ex 
vivo platelet activation. Removing a potential source of 
preanalytical error should reduce the inherent variability 
of TGFβ measurements in patients, and allow for a better 
evaluation of the true utility of circulating TGFβ levels as 
a cancer biomarker. Further work applying this technique 
to well-annotated clinical specimens will be required to 
determine the value of circulating TGFβ levels as a poten-
tial prognostic tool.
Disclosure
The authors report no conﬂ  icts of interest in this work.
References
Assoian RK, Sporn MB. 1986. Type beta transforming growth factor in 
human platelets: release during platelet degranulation and action on 
vascular smooth muscle cells. J Cell Biol, 102:1217–23.
Baselga J, Rothenberg ML, Tabernero J, et al. TGF-β signaling related mark-
ers in cancer patients with bone metastasis. Biomarkers, 13:217–36.
Blobe GC, Schiemann WP, Lodish HF. 2000. Role of transforming growth 
factor beta in human disease. N Engl J Med, 342:1350–8.
Caine GJ, Stonelake PS, Lip GY, et al. 2002. The hypercoagulable state of 
malignancy: pathogenesis and current debate. Neoplasia (New York), 
4:465–73.
Contant G, Gouault-Heilmann M, Martinoli JL. 1983. Heparin inactivation 
during blood storage: Its prevention by blood collection in citric acid, 
theophylline, adenosine, dipyridamole-C.T.A.D. mixture. Thromb Res, 
31:365–74.
Culhaci N, Sagol O, Karademir S, et al. 2005. Expression of transforming 
growth factor-beta-1 and p27Kip1 in pancreatic adenocarcinomas: 
relation with cell-cycle-associated proteins and clinicopathologic 
characteristics. BMC Cancer, 5:98.
Golanski J, Pietrucha T, Baj Z, et al. 1996. Molecular insights into the 
anticoagulant-induced spontaneous activation of platelets in whole 
blood – various anticoagulants are not equal. Thromb Res, 83:199–216.
Gordinier ME, Zhang HZ, Patenia R, et al. 1999. Quantitative analysis of 
transforming growth factor beta 1 and 2 in ovarian carcinoma. Clin 
Cancer Res, 5:2498–505.
Hazelbag S, Kenter GG, Gorter A, et al. 2004. Prognostic relevance of TGF-
beta1 and PAI-1 in cervical cancer. Int J Cancer, 112:1020–8.
Kang Y, He W, Tulley S, et al. 2005. Breast cancer bone metastasis medi-
ated by the Smad tumor suppressor pathway. Proc Natl Acad Sci USA, 
102:13909–14.
Kaplan KL, Owen J. 1981. Plasma levels of beta-thromboglobulin and 
platelet factor 4 as indices of platelet activation in vivo. Blood, 
57:199–202.
Kropf J, Schurek JO, Wollner A, et al. 1997. Immunological measurement 
of transforming growth factor-beta 1 (TGF-β1) in blood; assay develop-
ment and comparison. Clin Chem, 43:1965–74.
Macey M, Azam U, McCarthy D, et al. 2002. Evaluation of the anticoagulants 
EDTA and citrate, theophylline, adenosine, and dipyridamole (CTAD) 
for assessing platelet activation on the ADVIA 120 hematology system. 
Clin Chem, 48:891–9.
Neufeld M, Nowak-Gottl U, Junker R. 1999. Citrate-theophylline-adenine-
dipyridamol buffer is preferable to citrate buffer as an anticoagulant for ﬂ  ow 
cytometric measurement of platelet activation. Clin Chem, 45:2030–3.
Nio Y, Omori H, Hashimoto K, et al. 2005. Immunohistochemical expres-
sion of receptor-tyrosine kinase c-kit protein and TGF-beta1 in invasive 
ductal carcinoma of the pancreas. Anticancer Res, 25:3523–9.
Philippe J, De Logi E, Baele G. 2004. Comparison of ﬁ  ve different citrated 
tubes and their in vitro effects on platelet activation. Clin Chem, 
50:656–8.Biologics: Targets & Therapy 2008:2(3) 569
TGFβ measurement in cancer patients
Reinhold D, Bank U, Buhling F, et al. 1997. A detailed protocol for the 
measurement of TGFb1 in human blood samples. J Immun Methods, 
209:203–6.
Roberts AB, Wakeﬁ  eld LM. 2003. The two faces of transforming growth 
factor beta in carcinogenesis [comment]. Proc Natl Acad Sci USA, 
100:8621–3.
Seyedin SM, Thomas TC, Thompson AY, et al. 1985. Puriﬁ  cation and 
characterization of two cartilage-inducing factors from bovine demin-
eralized bone. Proc Natl Acad Sci USA, 82:2267–71.
Shariat SF, Shalev M, Menesses-Diaz A, et al. 2001. Preoperative plasma 
levels of transforming growth factor beta(1) (TGF-beta(1)) strongly 
predict progression in patients undergoing radical prostatectomy. 
J Clin Oncol, 19:2856–64.
Siegel PM, Massague J. 2003. Cytostatic and apoptotic actions of TGF-beta 
in homeostasis and cancer. Nature Rev Cancer, 3:807–21.
Wakeﬁ  eld LM, Letterio JJ, Chen T, et al. 1995. Transforming growth factor-
beta1 circulates in normal human plasma and is unchanged in advanced 
metastatic breast cancer. Clin Cancer Res, 1:129–36.
Yamamoto T, Akisue T, Marui T, et al. 2004. Expression of transforming 
growth factor beta isoforms and their receptors in malignant ﬁ  brous 
histiocytoma of soft tissues. Clin Cancer Res, 10:5804–7.
Zimmermann R, Koenig J, Zingsem J, et al. 2005. Effect of specimen anti-
coagulation on the measurement of circulating platelet-derived growth 
factors. Clin Chem, 51:2365–8.